Targeted therapies in multiple myeloma

Targeted Oncology

Volumn 4, Issue 1, 2009, Pages 23-36

  Kastritis, Efstathios ^a   Charidimou, Andreas ^a   Varkaris, Andreas ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Angiogenesis; Bcl 2; Heat shock protein 90 inhibitors; Histone deacetylase inhibitors; IMiDs; Lenalidomide; MTOR; Pomalidomide; Proteasome inhibitors; Thalidomide

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 11 AAG; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; 4 N ACETYLDINALINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AB 1010; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARFLIZOMIB; CHIR 12.12; CNTO 328; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; GW 654652; IMC A 12; LENALIDOMIDE; MASITINIB; MELPHALAN; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NVP AUY 922; OBLIMERSEN; PANOBINOSTAT; PAZOPANIB; PERIFOSINE; POMALIDOMIDE; PR 171; RAPAMYCIN; SALINOSPORAMIDE A; SANT 7; SGN 40; SU 10991; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VORINOSTAT;

BONE MARROW; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MICROENVIRONMENT; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349238174     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0102-9     Document Type: Review

References (136)

1. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520
2. CS Mitsiades DW McMillin S Klippel T Hideshima D Chauhan PG Richardson 2007 The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies Hematol Oncol Clin North Am 21 1007 1034 (Pubitemid 350051349)
3. K Podar PG Richardson T Hideshima D Chauhan KC Anderson 2007 The malignant clone and the bone-marrow environment Best Pract Res Clin Haematol 20 597 612 (Pubitemid 350215375)
4. T Hideshima K Podar D Chauhan KC Anderson 2005 Cytokines and signal transduction Best Pract Res Clin Haematol 18 509 524 (Pubitemid 40984111)
5. B Klein XG Zhang ZY Lu R Bataille 1995 Interleukin-6 in human multiple myeloma Blood 85 863 872
6. M Trikha R Corringham B Klein JF Rossi 2003 Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence Clin Cancer Res 9 4653 4665 (Pubitemid 37323267)
7. PM Voorhees Q Chen DJ Kuhn GW Small SA Hunsucker JS Strader 2007 Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma Clin Cancer Res 13 6469 6478 (Pubitemid 350075037)
8. A Demartis F Bernassola R Savino G Melino G Ciliberto 1996 Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death Cancer Res 56 4213 4218 (Pubitemid 26305018)
9. D Honemann M Chatterjee R Savino K Bommert R Burger M Gramatzki 2001 The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells Int J Cancer 93 674 680 (Pubitemid 32695115)
10. P Tassone P Neri R Burger R Savino M Shammas L Catley 2005 Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma Clin Cancer Res 11 4251 4258 (Pubitemid 40791592)
11. EA Bohula MP Playford VM Macaulay 2003 Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment Anticancer Drugs 14 669 682 (Pubitemid 37357691)
12. J Riedemann VM Macaulay 2006 IGF1R signalling and its inhibition Endocr Relat Cancer 13 Suppl 1 S33 43 (Pubitemid 46219247)
13. CS Mitsiades NS Mitsiades CJ McMullan V Poulaki R Shringarpure M Akiyama 2004 Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Cancer Cell 5 221 230 (Pubitemid 38402114)
14. E Menu H Jernberg-Wiklund T Stromberg H De Raeve L Girnita O Larsson 2006 Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model Blood 107 655 660 (Pubitemid 43076391)
15. E Menu H Jernberg-Wiklund H De Raeve E De Leenheer L Coulton O Gallagher 2007 Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival Int J Cancer 121 1857 1861 (Pubitemid 47417307)
16. EK Rowinsky H Youssoufian JR Tonra P Solomon D Burtrum DL Ludwig 2007 IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor Clin Cancer Res 13 5549s 5555s (Pubitemid 47510386)
17. JJ Westendorf GJ Ahmann JA Lust RC Tschumper PR Greipp JA Katzmann 1995 Molecular and biological role of CD40 in multiple myeloma Curr Top Microbiol Immunol 194 63 72
18. C Pellat-Deceunynck R Bataille N Robillard JL Harousseau MJ Rapp N Juge-Morineau 1994 Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells Blood 84 2597 2603 (Pubitemid 24317392)
19. YT Tai K Podar D Gupta B Lin G Young M Akiyama 2002 CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells Blood 99 1419 1427 (Pubitemid 34547100)
20. YT Tai K Podar N Mitsiades B Lin C Mitsiades D Gupta 2003 CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood 101 2762 2769 (Pubitemid 36857641)
21. M Urashima D Chauhan M Hatziyanni A Ogata D Hollenbaugh A Aruffo 1996 CD40 ligand triggers interleukin-6 mediated B cell differentiation Leuk Res 20 507 515 (Pubitemid 26254540)
22. YT Tai LP Catley CS Mitsiades R Burger K Podar R Shringpaure 2004 Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications Cancer Res 64 2846 2852 (Pubitemid 38500624)
23. YT Tai X Li X Tong D Santos T Otsuki L Catley 2005 Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma Cancer Res 65 5898 5906 (Pubitemid 40911196)
24. T Hayashi SP Treon T Hideshima YT Tai M Akiyama P Richardson 2003 Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells Br J Haematol 121 592 596 (Pubitemid 36645380)
25. YT Tai XF Li L Catley R Coffey I Breitkreutz J Bae 2005 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications Cancer Res 65 11712 11720 (Pubitemid 41821732)
26. ED Hsi R Steinle B Balasa S Szmania A Draksharapu BP Shum 2008 CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin Cancer Res 14 2775 2784
27. YT Tai M Dillon W Song M Leiba XF Li P Burger 2008 Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood 112 1329 1337
28. W Song Y-T Tai T Sasada P Burger M Fulciniti X Li 2007 Identification of CS1 peptides for induction of antigen-specific CTLs in multiple myeloma ASH Annual Meeting Abstracts 110 1611
29. A Rice M Dillon A van Abbema L Jesaitis M Wong S Lawson 2006 Eradication of tumors in pre-clinical models of multiple myeloma by anti-CS1 monoclonal antibody HuLuc63: mechanism of action studies ASH Annual Meeting Abstracts 108 3503
30. W Bensinger J Zonder S Singhal A Mohrbacher RM Dean F van Rhee 2007 Phase I trial of HuLuc63 in multiple myeloma ASH Annual Meeting Abstracts 110 1180
31. D Ribatti A Vacca F Dammacco D English 2003 Angiogenesis and anti-angiogenesis in hematological malignancies J Hematother Stem Cell Res 12 11 22 (Pubitemid 36314695)
32. D Ribatti B Nico A Vacca 2006 Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma Oncogene 25 4257 4266 (Pubitemid 44100496)
33. SV Rajkumar RA Mesa R Fonseca G Schroeder MF Plevak A Dispenzieri 2002 Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis Clin Cancer Res 8 2210 2216 (Pubitemid 34753592)
34. SV Rajkumar T Leong PC Roche R Fonseca A Dispenzieri MQ Lacy 2000 Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 6 3111 3116 (Pubitemid 30637735)
35. K Podar KC Anderson 2005 The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 105 1383 1395 (Pubitemid 40223651)
36. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 (Pubitemid 36910021)
37. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 (Pubitemid 38702844)
38. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676
39. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550
40. M Raschko S Markovina S Miyamoto W Longo E Williams T McFarland 2007 Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM) ASH Annual Meeting Abstracts 110 1173
41. MJ Kovacs DE Reece D Marcellus RM Meyer S Mathews RP Dong 2006 A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145 Invest New Drugs 24 529 535 (Pubitemid 44273029)
42. M Zangari E Anaissie A Stopeck A Morimoto N Tan J Lancet 2004 Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma Clin Cancer Res 10 88 95 (Pubitemid 38114166)
43. K Podar G Tonon M Sattler YT Tai S Legouill H Yasui 2006 The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma Proc Natl Acad Sci U S A 103 19478 19483 (Pubitemid 46026056)
44. GJ Morgan B Krishnan M Jenner FE Davies 2006 Advances in oral therapy for multiple myeloma Lancet Oncol 7 316 325
45. H Avet-Loiseau JY Li T Facon C Brigaudeau N Morineau F Maloisel 1998 High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies Cancer Res 58 5640 5645 (Pubitemid 29006396)
46. JJ Keats T Reiman CA Maxwell BJ Taylor LM Larratt MJ Mant 2003 In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression Blood 101 1520 1529 (Pubitemid 36182529)
47. EK Grand AJ Chase C Heath A Rahemtulla NC Cross 2004 Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074 Leukemia 18 962 966 (Pubitemid 38714621)
48. JL Paterson Z Li XY Wen E Masih-Khan H Chang JB Pollett 2004 Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma Br J Haematol 124 595 603 (Pubitemid 38297091)
49. S Trudel S Ely Y Farooqi M Affer DF Robbiani M Chesi 2004 Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma Blood 103 3521 3528 (Pubitemid 38525687)
50. B Arnulf D Ghez V Leblond S Choquet K Belhadj M Macro 2007 FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma ASH Annual Meeting Abstracts 110 413
51. T Hideshima L Catley H Yasui K Ishitsuka N Raje C Mitsiades 2006 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood 107 4053 4062 (Pubitemid 43726814)
52. C Gajate F Mollinedo 2007 Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts Blood 109 711 719 (Pubitemid 46105973)
53. P Richardson A Jakubowiak J Wolf J Allerton J Zonder S Lonial 2007 Phase I/II report from a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma previously treated with bortezomib ASH Annual Meeting Abstracts 110 1170
54. A Jakubowiak T Zimmerman M Alsina P Richardson J Kaufman T Kendall 2007 A Multiple Myeloma Research Consortium (MMRC) multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM): updated results ASH Annual Meeting Abstracts 110 1169
55. P Richardson S Lonial A Jakubowiak A Krishnan J Wolf J Densmore 2007 Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity ASH Annual Meeting Abstracts 110 1164
56. H Yan P Frost Y Shi B Hoang S Sharma M Fisher 2006 Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis Cancer Res 66 2305 2313 (Pubitemid 43294944)
57. A Fasolo C Sessa 2008 mTOR inhibitors in the treatment of cancer Expert Opin Investig Drugs 17 1717 1734
58. P Frost F Moatamed B Hoang Y Shi J Gera H Yan 2004 In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model Blood 104 4181 4187 (Pubitemid 39620172)
59. T Stromberg A Dimberg A Hammarberg K Carlson A Osterborg K Nilsson 2004 Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone Blood 103 3138 3147 (Pubitemid 38451692)
60. N Raje S Kumar T Hideshima K Ishitsuka D Chauhan C Mitsiades 2004 Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma Blood 104 4188 4193 (Pubitemid 39620173)
61. LK Francis Y Alsayed X Leleu X Jia UK Singha J Anderson 2006 Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma Clin Cancer Res 12 6826 6835
62. YT Tai M Fulciniti T Hideshima W Song M Leiba XF Li 2007 Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis Blood 110 1656 1663 (Pubitemid 47443984)
63. I Breitkreutz MS Raab S Vallet T Hideshima N Raje D Chauhan 2007 Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma Br J Haematol 139 55 63 (Pubitemid 47389922)
64. D Chauhan KC Anderson 2003 Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications Apoptosis 8 337 343 (Pubitemid 36935205)
65. WW Wong H Puthalakath 2008 Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway IUBMB Life 60 390 397
66. AA Chanan-Khan R Niesvizky RJ Hohl TM Zimmerman NP Christiansen GJ Schiller 2004 Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM) ASH Annual Meeting Abstracts 104 1477
67. MP Kline SV Rajkumar MM Timm TK Kimlinger JL Haug JA Lust 2007 ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells Leukemia 21 1549 1560 (Pubitemid 46965297)
68. S Trudel AK Stewart Z Li Y Shu SB Liang Y Trieu 2007 The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan Clin Cancer Res 13 621 629 (Pubitemid 46225369)
69. D Chauhan M Velankar M Brahmandam T Hideshima K Podar P Richardson 2007 A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma Oncogene 26 2374 2380 (Pubitemid 46572819)
70. T Hideshima D Chauhan P Richardson KC Anderson 2005 Identification and validation of novel therapeutic targets for multiple myeloma J Clin Oncol 23 6345 6350 (Pubitemid 46218845)
71. E Jabbour H Kantarjian J Cortes 2004 Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action Leuk Lymphoma 45 2187 2195 (Pubitemid 39504312)
72. M Alsina R Fonseca EF Wilson AN Belle E Gerbino T Price-Troska 2004 Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma Blood 103 3271 3277 (Pubitemid 38525650)
73. E Jabbour H Kantarjian J Cortes 2007 Clinical activity of tipifarnib in hematologic malignancies Expert Opin Investig Drugs 16 381 392 (Pubitemid 46394861)
74. E David SY Sun EK Waller J Chen FR Khuri S Lonial 2005 The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT Blood 106 4322 4329 (Pubitemid 41775943)
75. R Sinha E David E Zeilter C Torre JL Kaufman S Lonial 2005 Combination of Akt/PKB inhibition (perifosine) and farnesyl transferase inhibition (tipifarnib) results in increased cell death in myeloma cells lines ASH Annual Meeting Abstracts 106 1568
76. N Mitsiades CS Mitsiades V Poulaki D Chauhan G Fanourakis X Gu 2002 Molecular sequelae of proteasome inhibition in human multiple myeloma cells Proc Natl Acad Sci U S A 99 14374 14379 (Pubitemid 35257679)
77. EA Obeng LM Carlson DM Gutman WJ Harrington Jr. KP Lee LH Boise 2006 Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 4907 4916 (Pubitemid 43882644)
78. S Cenci R Sitia 2007 Managing and exploiting stress in the antibody factory FEBS Lett 581 3652 3657 (Pubitemid 47081003)
79. K Anargyrou MA Dimopoulos O Sezer E Terpos 2008 Novel anti-myeloma agents and angiogenesis Leuk Lymphoma 49 677 689
80. E Terpos O Sezer P Croucher MA Dimopoulos 2007 Myeloma bone disease and proteasome inhibition therapies Blood 110 1098 1104 (Pubitemid 47281403)
81. RH Feling GO Buchanan TJ Mincer CA Kauffman PR Jensen W Fenical 2003 Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora Angew Chem Int Ed Engl 42 355 357 (Pubitemid 36176323)
82. PG Williams GO Buchanan RH Feling CA Kauffman PR Jensen W Fenical 2005 New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica J Org Chem 70 6196 6203 (Pubitemid 41076500)
83. D Chauhan L Catley G Li K Podar T Hideshima M Velankar 2005 A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib Cancer Cell 8 407 419 (Pubitemid 41579835)
84. D Chauhan T Hideshima KC Anderson 2006 A novel proteasome inhibitor NPI-0052 as an anticancer therapy Br J Cancer 95 961 965 (Pubitemid 44606819)
85. D Chauhan A Singh M Brahmandam K Podar T Hideshima P Richardson 2008 Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood 111 1654 1664
86. SD Demo CJ Kirk MA Aujay TJ Buchholz M Dajee MN Ho 2007 Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res 67 6383 6391 (Pubitemid 47037522)
87. DJ Kuhn Q Chen PM Voorhees JS Strader KD Shenk CM Sun 2007 Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood 110 3281 3290 (Pubitemid 350106321)
88. C Stapnes AP Doskeland K Hatfield E Ersvaer A Ryningen JB Lorens 2007 The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells Br J Haematol 136 814 828 (Pubitemid 46348414)
89. M Alsina S Trudel M Vallone C Molineaux L Kunkel A Goy 2007 Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies ASH Annual Meeting Abstracts 110 411
90. RZ Orlowski K Stewart M Vallone C Molineaux L Kunkel J Gericitano 2007 Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results ASH Annual Meeting Abstracts 110 409
91. N Mitsiades CS Mitsiades PG Richardson C McMullan V Poulaki G Fanourakis 2003 Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 4055 4062 (Pubitemid 36857886)
92. DC Drummond CO Noble DB Kirpotin Z Guo GK Scott CC Benz 2005 Clinical development of histone deacetylase inhibitors as anticancer agents Annu Rev Pharmacol Toxicol 45 495 528 (Pubitemid 40261815)
93. CS Mitsiades NS Mitsiades CJ McMullan V Poulaki R Shringarpure T Hideshima 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A 101 540 545 (Pubitemid 38084672)
94. P Richardson C Mitsiades K Colson E Reilly L McBride J Chiao 2008 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 502 507
95. A Badros S Philip R Niesvizky O Goloubeva C Harris J Zweibel 2007 Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts) ASH Annual Meeting Abstracts 110 1168
96. DM Weber S Jagannath A Mazumder R Sobecks GJ Schiller M Gavino 2007 Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma ASH Annual Meeting Abstracts 110 1172
97. L Catley E Weisberg YT Tai P Atadja S Remiszewski T Hideshima 2003 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2615 2622 (Pubitemid 37193603)
98. P Maiso X Carvajal-Vergara EM Ocio R Lopez-Perez G Mateo N Gutierrez 2006 The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 66 5781 5789 (Pubitemid 43927132)
99. CS Mitsiades PJ Hayden KC Anderson PG Richardson 2007 From the bench to the bedside: emerging new treatments in multiple myeloma Best Pract Res Clin Haematol 20 797 816 (Pubitemid 350215385)
100. HM Prince M Bishton S Harrison 2008 The potential of histone deacetylase inhibitors for the treatment of multiple myeloma Leuk Lymphoma 49 385 387
101. S Lentzsch G Anderson C Li CP Belani MY Mapara D Roodman 2005 Combination of proteasome inhibitor PS 341 (Velcade(R)) with histone acetylase inhibitor (HDAC) PXD 101 shows superior anti-myeloma activity and inhibits osteoclastogenesis ASH Annual Meeting Abstracts 106 2488
102. SB Khan T Maududi K Barton J Ayers S Alkan 2004 Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma Br J Haematol 125 156 161 (Pubitemid 38534966)
103. R Feng H Ma CA Hassig JE Payne ND Smith MY Mapara 2008 KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling Mol Cancer Ther 7 1494 1505
104. DB Solit N Rosen 2006 Hsp90: a novel target for cancer therapy Curr Top Med Chem 6 1205 1214 (Pubitemid 44120915)
105. CS Mitsiades NS Mitsiades CJ McMullan V Poulaki AL Kung FE Davies 2006 Antimyeloma activity of heat shock protein-90 inhibition Blood 107 1092 1100 (Pubitemid 43156310)
106. J Duus HI Bahar G Venkataraman F Ozpuyan KF Izban H Al-Masri 2006 Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma Leuk Lymphoma 47 1369 1378 (Pubitemid 44269648)
107. EL Davenport HE Moore AS Dunlop SY Sharp P Workman GJ Morgan 2007 Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 2641 2649 (Pubitemid 47523188)
108. J Patterson VJ Palombella C Fritz E Normant 2008 IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells Cancer Chemother Pharmacol 61 923 932
109. PG Richardson AA Chanan-Khan M Alsina D Doss B Landrigan D Kettner 2005 Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): interim results of a phase 1 trial ASH Annual Meeting Abstracts 106 361
110. PG Richardson A Chanan-Khan S Lonial A Krishman M Carroll GF Cropp 2007 Tanespimycin (T) + gortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation ASH Annual Meeting Abstracts 110 1165
111. S Pacey U Banerji I Judson P Workman 2006 Hsp90 inhibitors in the clinic Handb Exp Pharmacol 2006 331 358
112. T Stuhmer A Zollinger D Siegmund M Chatterjee E Grella S Knop 2008 Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma Leukemia 22 1604 1612
113. A Huston X Leleu X Jia AS Moreau HT Ngo J Runnels 2008 Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment Clin Cancer Res 14 865 874
114. S Singhal J Mehta R Desikan D Ayers P Roberson P Eddlemon 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571
115. JB Bartlett K Dredge AG Dalgleish 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 4 314 322 (Pubitemid 38525287)
116. PG Richardson RL Schlossman E Weller T Hideshima C Mitsiades F Davies 2002 Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 3063 3067 (Pubitemid 35217050)
117. SA Schey P Fields JB Bartlett IA Clarke G Ashan RD Knight 2004 Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma J Clin Oncol 22 3269 3276 (Pubitemid 41103682)
118. KC Anderson 2005 Lenalidomide and thalidomide: mechanisms of action-similarities and differences Semin Hematol 42 S3 8 (Pubitemid 41774590)
119. T Hideshima PL Bergsagel WM Kuehl KC Anderson 2004 Advances in biology of multiple myeloma: clinical applications Blood 104 607 618 (Pubitemid 38970551)
120. F Payvandi L Wu M Haley PH Schafer LH Zhang RS Chen 2004 Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner Cell Immunol 230 81 88 (Pubitemid 39626649)
121. K Dredge JB Marriott CD Macdonald HW Man R Chen GW Muller 2002 Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects Br J Cancer 87 1166 1172 (Pubitemid 35418112)
122. N Mitsiades CS Mitsiades V Poulaki D Chauhan PG Richardson T Hideshima 2002 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 4525 4530 (Pubitemid 34627223)
123. CS Mitsiades N Mitsiades 2004 CC-5013 (Celgene) Curr Opin Investig Drugs 5 635 647
124. AK Gandhi J Kang S Naziruddin A Parton PH Schafer DI Stirling 2006 Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leuk Res 30 849 858 (Pubitemid 43816707)
125. CS Mitsiades NS Mitsiades PG Richardson NC Munshi KC Anderson 2007 Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment J Cell Biochem 101 950 968 (Pubitemid 47040875)
126. HR Gockel A Lugering J Heidemann M Schmidt W Domschke T Kucharzik 2004 Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway J Immunol 172 5103 5109 (Pubitemid 38456439)
127. PA Haslett LG Corral M Albert G Kaplan 1998 Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med 187 1885 1892 (Pubitemid 28262451)
128. PA Haslett WA Hanekom G Muller G Kaplan 2003 Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro J Infect Dis 187 946 955 (Pubitemid 36337907)
129. PA Haslett JD Klausner S Makonkawkeyoon A Moreira P Metatratip B Boyle 1999 Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients AIDS Res Hum Retroviruses 15 1169 1179 (Pubitemid 29411802)
130. LG Corral PA Haslett GW Muller R Chen LM Wong CJ Ocampo 1999 Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 380 386 (Pubitemid 29295864)
131. LG Corral G Kaplan 1999 Immunomodulation by thalidomide and thalidomide analogues Ann Rheum Dis 58 Suppl 1 I107 I113
132. R LeBlanc T Hideshima LP Catley R Shringarpure R Burger N Mitsiades 2004 Immunomodulatory drug co-stimulates T cells via the B7-CD28 pathway Blood 103 1787 1790 (Pubitemid 38268973)
133. FE Davies N Raje T Hideshima S Lentzsch G Young YT Tai 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216
134. D Stirling 2001 Thalidomide: a novel template for anticancer drugs Semin Oncol 28 602 606 (Pubitemid 33134419)
135. A Vacca C Scavelli V Montefusco G Di Pietro A Neri M Mattioli 2005 Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma J Clin Oncol 23 5334 5346 (Pubitemid 46206987)
136. L Coultas K Chawengsaksophak J Rossant 2005 Endothelial cells and VEGF in vascular development Nature 438 937 945 (Pubitemid 43093959)